Final overall survival results are now awaited to confirm the place of the combination treatment as a standard approach

Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up

Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles

Although further evidence is needed, targeting mutant KRAS with novel agents and combinations may offer new options for patients with advanced colorectal cancer

Although not immediately practice-changing, impressive results from the NICHE-2 trial may open a way to a ‘watch and wait’ approach for some patients

Disease-free and overall survival in the PRODIGE-24/CCTG PA6 study were significantly higher in GemPred-positive versus GemPred-negative patients who received adjuvant gemcitabine

Two early studies investigate the anticancer activity of derazantinib and RLY-4008 in patients with FGFR inhibitor-naïve cholangiocarcinoma  

Updated overall survival data from TOPAZ-1 confirm clinically meaningful benefit of adding durvalumab to cisplatin/gemcitabine 

Standard second-line chemotherapy may benefit fit patients but efficacy is limited and new treatments are urgently needed

Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy